Pfizer’s chief executive has called on Washington to support its $160bn takeover of Dublin-based Allergan the Financial Times reported. This is in response to politicians including Hillary Clinton that are lined up against the drugmaker’s attempt to slash its tax bill by moving overseas.
The third-largest announced deal in history caps a frenzied year of mergers and acquisitions, bringing the total value of global transactions announced since the start of 2015 to more than $4.2tn. This surpasses the previous record set in 2007 on the eve of the financial crisis, according to Thomson Reuters.
In an attempt to circumvent any political attempt to torpedo the deal, the transaction will be structured as a reverse merger, with Allergan technically buying Pfizer. Allergan will be renamed Pfizer and the new company will continue to trade on the New York Stock Exchange under the PFE ticker.
Full content: The Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Apple Faces Contempt Hearings Over App Store Reforms
May 19, 2024 by
CPI
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI